ClinicalTrials.gg
CompletedNCT00291382Updated May 30, 2017

Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product

A Phase 4 interventional study of Salmeterol/fluticasone propionate combination in Asthma, sponsored by GlaxoSmithKline. Completed at 35 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2005, registered Feb 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
23rd of 46
150 · median 128
Started
2005
with 5 others
Phase 4
26 of 46
none open now
Registered
10th of 46
by date
Lead sponsor
22 of 46
GlaxoSmithKline

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 23rd largest by enrollment, is one of 6 that started in 2005, is one of 26 in phase 4, and was the 10th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

This double-blind, stratified, parallel group study is to determine whether aiming for 'Total control' results in better airway hyper-responsiveness than maintaining the treatment level at which 'Well-controlled' asthma was achieved. The primary endpoint is the mean change in PC20 methacholine. Well controlled subjects (as assessed after a 12 week run-in period) will enter a 24 week treatment period during which they will record PEF(Peak Expiratory Flow), symptoms, rescue beta2-agonist use over 24 hours, night time awakenings, asthma exacerbations, emergency visits due to asthma and Adverse Events. At every visit lung function measurements and airway hyper-responsiveness will be measured.

Read the detailed description

A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for 'Total control' results in better airway hyper-responsiveness than a treatment strategy based on maintaining the treatment level at which 'Well-controlled' asthma was achieved.

03

Conditions studied

  • Asthma

Keywords

  • Total asthma control
  • airway hyper-responsiveness
  • adult
  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of asthma of at least 6 months.
  • Subjects who have received fluticasone propionate at a dose of 100 mcg bd to 250 mcg bd or equivalent with or without a long acting beta2-agonist for at least 4 weeks before the start of the run-in period, at a constant dose.
  • Subjects who are able to understand and complete an electronic diary card.

Exclusion criteria

Exclusion criteria:

  • Subjects who have been hospitalized for their asthma within 4 weeks of study entry.
  • Subjects who had an acute upper respiratory tract infection within 4 weeks or a lower respiratory tract infection within 4 weeks prior to study entry.
  • Subjects who received oral, parental or depot within 4 weeks prior to study entry.
  • Subjects who have a known respiratory disorder other than asthma and/or systemic/thoracic abnormalities which influence normal lung function.
  • Subjects who have more than 5 pack years.
  • Subjects who currently smoke.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in PC20 methacholine (as a measure of airway hyper-responsiveness) following 24 weeks of treatment.

Secondary outcomes

  1. Number of 'Totally-controlled' and Well-controlled patients at the end of the run-in and treatment period according to the GOAL criteria.

07

Study locations

35 sites
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Jyvaskyla, 40100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Lille cedex, 59042, France
  • GSK Investigational Site
    Montpellier, 34295, France
  • GSK Investigational Site
    Poitiers, 86000 cedex, France
  • GSK Investigational Site
    Sinsheim, Baden-Wuerttemberg 74889, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53123, Germany
  • GSK Investigational Site
    Berlin, 10559, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Berlin, 13359, Germany
  • GSK Investigational Site
    Torrette (AN), Marche 60020, Italy
  • GSK Investigational Site
    Foggia, Puglia 71100, Italy
  • GSK Investigational Site
    Cagliari, Sardegna 09126, Italy
  • GSK Investigational Site
    Pisa, Toscana 56124, Italy
  • GSK Investigational Site
    Bussolengo (VR), Veneto 37012, Italy
  • GSK Investigational Site
    Salerno, 84100, Italy
  • GSK Investigational Site
    Riga, LV 1003, Latvia
  • GSK Investigational Site
    Riga, LV 1035, Latvia
  • GSK Investigational Site
    Breda, 4819 EV, Netherlands
  • GSK Investigational Site
    Groningen, 9721 SW, Netherlands
  • GSK Investigational Site
    Harderwijk, 3844 DG, Netherlands
  • GSK Investigational Site
    Helmond, 5707 HA, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Nieuwegein, 3435 CM, Netherlands
  • GSK Investigational Site
    Veldhoven, 5504 DB, Netherlands
  • GSK Investigational Site
    Barcelona, 08022, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Tarrasa, Barcelona, 08221, Spain
  • GSK Investigational Site
    Valencia, 46017, Spain
  • GSK Investigational Site
    Göteborg, SE-413 45, Sweden
  • GSK Investigational Site
    Linköping, SE-585 81, Sweden
  • GSK Investigational Site
    Lund, SE-221 85, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Jul 2007, 20 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 20 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2006
First posted
Feb 14, 2006
StartActual
Nov 2005
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00291382
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 14, 2006
Start date
Nov 2005
Primary completion
Jul 2007
Completion
Jul 2007
Last update
May 30, 2017

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion